Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial - SELECT TDCS: Design, rationale and objectives

Página do item simplificado
dc.contributor.authorBrunoni A.R.
dc.contributor.authorValiengo L.
dc.contributor.authorBaccaro A.
dc.contributor.authorZanao T.A.
dc.contributor.authorde Oliveira J.F.
dc.contributor.authorVieira G.P.
dc.contributor.authorBueno V.F.
dc.contributor.authorGoulart A.C.
dc.contributor.authorBoggio P.S.
dc.contributor.authorLotufo P.A.
dc.contributor.authorBensenor I.M.
dc.contributor.authorFregni F.
dc.date.accessioned2024-03-13T01:29:39Z
dc.date.available2024-03-13T01:29:39Z
dc.date.issued2011
dc.description.abstractBackground: Despite significant advancements in psychopharmacology, treating major depressive disorder (MDD) is still a challenge considering the efficacy, tolerability, safety, and economical costs of most antidepressant drugs. One approach that has been increasingly investigated is modulation of cortical activity with tools of non-invasive brain stimulation - such as transcranial magnetic stimulation and transcranial direct current stimulation (tDCS). Due to its profile, tDCS seems to be a safe and affordable approach. Methods and design: The SELECT TDCS trial aims to compare sertraline vs. tDCS in a double-blinded, randomized, factorial trial enrolling 120 participants to be allocated to four groups to receive sertraline. +. tDCS, sertraline, tDCS or placebo. Eligibility criteria are moderate-to-severe unipolar depression (Hamilton Depression Rating Scale > 17) not currently on sertraline treatment. Treatment will last 6. weeks and the primary outcome is depression change in the Montgomery-Asberg Depression Rating Score (MADRS). Potential biological markers that mediate response, such as BDNF serum levels, Val66Met BDNF polymorphism, and heart rate variability will also be examined. A neuropsychological battery with a focus on executive functioning will be administered. Discussion: With this design we will be able to investigate whether tDCS is more effective than placebo in a sample of patients free of antidepressants and in addition, we will be able to secondarily compare the effect sizes of sertraline vs. tDCS and also the comparison between tDCS and combination of tDCS and sertraline. © 2010 Elsevier Inc.
dc.description.firstpage90
dc.description.issuenumber1
dc.description.lastpage98
dc.description.volume32
dc.identifier.doi10.1016/j.cct.2010.09.007
dc.identifier.issn1551-7144
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/37079
dc.relation.ispartofContemporary Clinical Trials
dc.rightsAcesso Restrito
dc.subject.otherlanguageAntidepressive agents
dc.subject.otherlanguageClinical trial
dc.subject.otherlanguageElectric stimulation therapy
dc.subject.otherlanguageFactorial design
dc.subject.otherlanguageMajor depressive disorder
dc.titleSertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial - SELECT TDCS: Design, rationale and objectives
dc.typeArtigo
local.scopus.citations56
local.scopus.eid2-s2.0-78649905804
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78649905804&origin=inward
Arquivos
Coleções
Artigos de periódico